TransThera Sciences (Nanjing), Inc.
藥捷安康（南京）科技股份有限公司

(A joint stock company incorporated in the People's Republic of China with limited liability)

(Stock Code: 2617)

VOLUNTARY ANNOUNCEMENT

FIRST PATIENT DOSED IN PHASE II CLINICAL TRIAL OF TINENGOTINIB IN COMBINATION WITH AKESO'S 開坦尼® (CADONILIMAB, PD-1/CTLA-4) /依達方® (IVONESCIMAB, PD-1/VEGF)

This announcement is made by TransThera Sciences (Nanjing), Inc. (the "**Company**", together with its subsidiaries, the "**Group**") on a voluntary basis to inform the shareholders and potential investors of the Company about the latest business advancement of the Group.

The board of directors of the Company (the "**Board**") is pleased to announce that the first patient has recently been dosed in the open-label, multicenter Phase II clinical study of the Company's Core Product Tinengotinib (TT-00420) in combination with Akeso, Inc. ("**Akeso**")'s 開坦尼® (cadonilimab, PD-1/CTLA-4)/依達方® (ivonescimab, PD-1/VEGF) for the treatment of advanced hepatocellular carcinoma (HCC).

This trial is an open-label, multicenter Phase II clinical study conducted in China to evaluate the efficacy and safety of 開坦尼® (cadonilimab, PD-1/CTLA-4)/依達方® (ivonescimab, PD-1/VEGF) in combination with Tinengotinib tablets for the treatment of advanced HCC. The primary objective is to assess the safety and efficacy of 開坦尼® (cadonilimab, PD-1/CTLA-4)/依達方® (ivonescimab, PD-1/VEGF) in combination with Tinengotinib tablets or Tinengotinib monotherapy in advanced HCC. The primary target population consists of patients with advanced HCC who have not previously received systemic anticancer therapy against HCC or who have failed prior standard treatments.

TransThera has entered into a collaboration agreement with Akeso to co-develop clinical combination therapies targeting HCC.

Warning under Rule 18A.08(3) of the Listing Rules: There is no assurance that the relevant products will ultimately be successfully developed and marketed by the Company.

By order of the Board
TransThera Sciences (Nanjing), Inc.
藥捷安康(南京)科技股份有限公司
Dr. Frank Wu
Chairman and Chief Executive Officer

Hong Kong, September 4, 2025

As at the date of this announcement, the Board comprises: (i) Dr. Frank Wu and Mr. Wu Di as executive directors; (ii) Ms. Jia Zhongxin and Dr. Yi Hua as non-executive directors; and (iii) Mr. Li Shu Pai, Ms. Chui Hoi Yam and Ms. Zheng Zhelan as independent non-executive directors.